Entries by admin

4P-Pharma will give a talk during the DDIP 2020

4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET. To learn more about 4P-Pharma, our pipeline […]

4P-Pharma est dans l’émission SMART FUTUR

Revital Rattenbach, Présidente de 4P-Pharma, a été interviewée dans l’émission SMART FUTUR diffusée le samedi 7 novembre 2020 sur BSMART. Lors de cette émission, Revital a présenté 4P-Pharma ainsi que les dernières innovations qui animent l’équipe : 4P004, notre traitement pour l’arthrose et 4P021, notre solution contre la COVID-19. Pour plus d’information : https://www.bsmart.fr/video/1121-smart-futur-emission-07-novembre-2020

Le Pr Francis Berenbaum reçoit le prix Fondation Guillaumat-Piel 2020 de la FRM

Toute l’équipe de 4P-Pharma est fière d’annoncer que le Pr Francis Berenbaum a remporté le prix Fondation Guillaumat-Piel 2020 de la Fondation pour la Recherche Médicale (FRM)  pour ses travaux sur les maladies ostéo-articulaires ! Nous collaborons avec Francis Berenbaum depuis plusieurs années sur le développement de 4P004, notre solution thérapeutique pour enrayer l’arthrose. Francis Berenbaum est […]

4P-Pharma will present 4P004 data at ACR Convergence 2020

Pr. Francis Berenbaum (Head of Rheumatology at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France) will present a poster on 4P004 entitled “Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect” (#0703) during the ACR Convergence 2020 annual meeting, November […]

4P-Pharma is in the “50 Fastest Growing Companies of the Year 2020”

4P-Pharma is in the Silicon Review’s “50 Fastest Growing Companies of the Year 2020” list. The Silicon Review recognizes worldwide companies to follow closely! Here you can find the Silicon Review’s interview of Revital Rattenbach, our chairwoman, and Patrice Denèfle, our CSO, about 4P-Pharma’s DNA and the challenging field of drug development:   https://thesiliconreview.com/magazine/profile/speed-up-innovation-with-4p-pharmas-unique-drug-discovery/

4P-Pharma appoints Sonia Escaich as Chief Operating Officer

4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer. “Sonia has deep domain expertise from both drug development and business perspective, she will bring a wealth of experience to the team”, said Revital Rattenbach, Founder and President […]

4P-Pharma appoints Patrice Denèfle as Chief Scientific Officer

4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).  “We are delighted to welcome Patrice to our team as Chief Scientific Officer. […] I look forward to work closely with him to […]